GlycoMimetics News

GlycoMimetics GAAP EPS of -$0.17 In-line

Seeking AlphaMay 10 02:25 ET

GlycoMimetics | 10-Q: Quarterly report

Futu NewsMay 9 16:36 ET · Announcements

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

Earnings Call TranscriptsMay 9 15:17 ET

Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50

Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50.

MT NewswiresMay 7 07:10 ET

Express News | GlycoMimetics Inc : Jefferies Cuts Target Price to $1 From $3

ReutersMay 7 00:14 ET

GlycoMimetics Announces Promising Phase 3 Leukemia Drug Results

TipRanksMay 6 16:13 ET

Lyra LYRA Phase 3 Fails; GlycoMimetics GLYC Phase 3 Dissapoints

BioPharmCatalystMay 6 15:56 ET

Sector Update: Health Care

Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 0.2%. In c

MT NewswiresMay 6 15:36 ET

GlycoMimetics' Uproleselan: Hold Rating Amidst Strategic Reevaluation and Uncertain Future

TipRanksMay 6 15:05 ET

HC Wainwright & Co. Downgrades GlycoMimetics to Neutral

HC Wainwright & Co. analyst Edward White downgrades GlycoMimetics from Buy to Neutral.

Analyst UpgradesMay 6 14:00 ET

GlycoMimetics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 — HC Wainwright & Co. Downgrades Buy → Neutral 03/27/2024 2092.32% HC Wainwright & Co. $8 → $8

BenzingaMay 6 13:59 ET

Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.18% to 38,744.60 while the NASDAQ rose 0.69% to 16,267.82. The S&

BenzingaMay 6 12:48 ET

GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint

GlycoMimetics (GLYC) shares were down 79% in recent Monday trading after the company said a late-stage study of uproleselan in combination with chemotherapy failed to meet its main goal in blood cance

MT NewswiresMay 6 12:45 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: GlycoMimetics (GLYC) and Gossamer Bio (GOSS)

TipRanksMay 6 12:10 ET

Express News | GlycoMimetics, Inc. : H.c. Wainwright Cuts to Neutral From Buy

ReutersMay 6 11:51 ET

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.25% to 38,772.28 while the NASDAQ rose 0.64% to 16,260.19. The S&P 500 also

BenzingaMay 6 11:14 ET

Express News | Shares of GlycoMimetics Hit Record Low After Blood Cancer Drug Fails in Late-Stage Trial, Last Down 81.3% to 34 Cents

ReutersMay 6 09:37 ET

GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink

On Monday, GlycoMimetics Inc. (NASDAQ:GLYC) announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML). In the study, uprole

BenzingaMay 6 09:13 ET

Lyra LYRA Phase 3 Data; GlycoMimetics GLYC Phase 3 Data

BioPharmCatalystMay 6 08:26 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s

BenzingaMay 6 08:06 ET